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Abstract: Postprandial hyperglycemia in type 2 diabetes is characterized by impaired insulin 
secretion and action, decreased glucose effectiveness and defective suppression of glucagon 
secretion. Newly available therapies for type 2 diabetes target the pathway of the incretin hormone 
glucagon-like peptide-1 (GLP-1). Oral inhibitors of dipeptidyl peptidase-4 (DPP-4) raise the 
level of endogenous GLP-1 by inhibiting its clearance thereby lowering fasting and postprandial 
glucose concentrations. Unlike compounds which act as agonists of the GLP-1 receptor, DPP-4 
inhibitors are not associated with significant effects on gastrointestinal motility, which led to 
a controversy around the mechanisms responsible for their glucose-lowering effects. Here we 
review the evidence in regards to the mechanisms whereby DPP-4 inhibitors lower glucose 
concentrations. Their effects are most likely mediated by an increase in endogenous GLP-1, 
although additional mechanisms may be involved. The pharmacology, efficacy and safety of 
vildagliptin, a novel DPP-4 inhibitor, are also discussed.
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Introduction
Of the 20.8 million Americans with diabetes, 90%–95% have type 2 diabetes. This 
disorder is primarily characterized by defective insulin secretion and action. Other 
mechanisms that contribute to postprandial hyperglycemia in patients with type 2 
diabetes are an impaired ability of glucose to stimulate its own uptake and suppress its 
own production (glucose effectiveness), defective suppression of glucagon secretion 
and possibly altered gastric motility.
Incretins are gut hormones that amplify insulin release in response to an oral 
glucose load. They include glucagon-like peptide (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP). Altered meal-stimulated GLP-1 secretion has 
been reported in people with type 2 diabetes. There is significant heterogeneity in 
these reports, with some studies showing 15%–20% impairment in GLP-1 secretion 
in patients with type 2 diabetes1–5 and others showing enhanced secretion6 or no 
difference in secretion.7 The role of GLP-1 in the pathogenesis of type 2 diabetes 
remains controversial. GLP-1 secretion was found to be reduced in subjects with 
impaired glucose tolerance as well as people with impaired fasting glucose, suggesting 
abnormalities of incretin secretion may be present early in pre-diabetes.8 The precise 
role that the alterations in GLP-1 secretion play in the pathogenesis of pre-diabetes 
and diabetes is at present uncertain.
Regardless of whether endogenous incretin secretion is altered, acute exogenous 
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gastric emptying,11 all of which result in a glucose-lowering 
effect. Interestingly, pharmacologic doses of exogenous GIP 
have not demonstrated the same insulinotropic potency and 
tend to result in negligible glucose-lowering in people with 
type 2 diabetes.12
The short half-life of GLP-1, due to its rapid degradation 
by the ubiquitous dipeptidyl peptidase-4 (DPP-4) enzyme, 
would require the hormone to be infused continuously to 
achieve therapeutic effect. This limitation to the therapeutic 
use of GLP-1 has been circumvented by the development of 
GLP-1 receptor agonists, resistant to the action of DPP-4, and 
of compounds that inhibit DPP-4, thereby raising endogenous 
concentrations of active GLP-1 and GIP (and perhaps 
other substrates of DPP-4). The arrival of incretin-based 
pharmacotherapy has been heralded by exenatide (a GLP-1 
receptor agonist) and sitagliptin (a DDP-4 inhibitor) both 
US Food and Drug Administration (FDA)-approved for 
the treatment of type 2 diabetes. Other compounds such as 
liraglutide, another GLP-1 receptor agonist and vildagliptin, a 
DPP-4 inhibitor, are expected to become available for clinical 
use in the near future.
Mechanisms of action
Endogenous GLP-1 and GIP are produced by L- and K-cells 
respectively, dispersed in intestinal mucosa. Both GLP-1 
and GIP are physiological substrates for DPP-4, which 
exists both as a cell surface-enzyme present on numerous 
cell types including kidney, enterocytes, hepatocytes, and 
endothelial cells, and as a soluble form in the circulation. 
The importance of DPP-4 in incretin inactivation in vivo was 
established in animal studies where peptide infusions into 
DPP-4 deficient rats resulted in reduced cleavage of intact 
GLP-1 (7–36) amide and GIP (1–42) to metabolites GLP-1 
(9–36) amide and GIP (3–42).13 Human studies confirmed 
that DPP-4 is a principal determinant of circulating half-life 
of GLP-1 and GIP in both normal and subjects with type 2 
diabetes.14,15
Other peptides and chemokines may also be subject to 
cleavage by DPP-4 if they contain alanine or proline at the 
second N-terminal position. Potential substrates include 
substance P, neuropeptide Y, peptide YY, and growth 
hormone-releasing hormone (GHRH). While these may be 
pharmacologic substrates, there is limited evidence that they 
are in fact physiologic substrates, where DPP-4 activity leads 
to biologically significant alterations in the endogenous levels 
of these substances (other than perhaps PYY).16
Its physiologic role in inactivating GLP-1 makes DPP-4 
enzyme a therapeutic target. Animal data suggests significant 
metabolic benefits of DPP-4 inhibition. Mice lacking DPP-4 
entirely were found to be resistant to high-fat diet- induced 
obesity and have lower insulin concentrations with a greater 
glucose-lowering efficacy.17 Diabetic rat models treated with 
a variety of DPP-4 inhibitors demonstrated improved glucose 
tolerance, insulin sensitivity and improved hyperinsulinemia 
in a series of studies.18–21 Islet histology in mice treated with 
DPP-4 inhibitors followed by streptozotocin revealed greater 
β-cell mass suggesting improved β-cell survival.22,23
Human studies show significantly lower fasting and 
post-prandial glucose values in people with type 2 diabetes 
treated with DPP-4 inhibitors compared to placebo-
treated subjects.24–26 DPP-4 inhibitors produce this effect 
by increasing insulin secretion and lowering glucagon 
concentrations. In studies where DDP-4 inhibitors were 
administered over the course of several days or weeks, 
glucose levels were lower but fasting insulin concentrations, 
insulin concentrations after meal ingestion and C-peptide 
concentrations were found to be unaltered.24–26 This implies 
that insulin secretion for a given glucose concentration is 
increased, indicating an improvement of β-cell function. 
Physiologic modeling of postprandial glucose, insulin and 
C-peptide revealed a 50% increase in the insulin secretion 
response to ambient glucose after six weeks of treatment with 
vildagliptin.25 Similar results were obtained with modeling 
β-cell responsivity after a single dose of vildagliptin27 and 
10 days of treatment with vildagliptin.28
The effect of DPP-4 inhibition on islet α-cells may be 
just as important as the effect on β-cells in improving both 
fasting and postprandial glycemia. Most studies have shown 
a decrease in meal-stimulated glucagon concentrations in 
patients treated with DPP-4 inhibitors.24–29 The effect may 
persist well beyond the immediate post-prandial period, 
lasting as long as 12 hours.27 Subjects with a more marked 
reduction in the glucagon response to meal ingestion seemed 
to have the largest reduction in glucose.25,26
Lower glucagon concentrations result in a decreased 
rate of endogenous glucose production (EGP) after a 
meal. In a single-dose administration study of vildagliptin 
which used a double tracer method, EGP suppression was 
statistically greater within 60 minutes of meal ingestion in 
vildagliptin-treated subjects compared to a placebo. The 
difference became progressively larger with time: EGP was 
25% lower within four hours and 59% lower at 14 hours 
post-meal.27 The enhanced suppression of EGP was noted 
to correlate with the increment in insulin to glucagon ratio. 
Similar findings of a reduction in post-prandial endogenous 
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treated with vildagliptin for six weeks.26 In our own study 
of vildagliptin administration to people with type 2 diabetes 
for 10 days, we did not observe a statistically significant 
difference in either fasting or post-prandial EGP.24 However, 
since glucose itself stimulates its own uptake and decreases 
glucagon production, comparable rates of endogenous 
glucose production at a lower plasma glucose level in the 
vildagliptin group, suggests that there is a net suppressive 
effect of vildagliptin on EGP.
The mechanism by which DPP-4 inhibition results in 
a lower glucagon secretion has not been established. One 
possibility is a direct inhibitory effect of GLP-1 on the α-cells. 
However, a study where glucagon levels were measured 
during a hypoglycemic clamp showed a 38% increase 
in glucagon response to hypoglycemia in vildagliptin-
treated subjects compared to the placebo group.30 In this 
same group of subjects, a standard meal resulted in a 41% 
decrease in postprandial glucagon compared to placebo. 
This suggests that DPP-4 inhibition produces an increased 
responsiveness of α-cells, rather than a unilateral inhibitory 
effect. An intriguing possibility is that the α-cells are more 
responsive to insulin in the presence of DPP-4 inhibition. In 
subjects receiving vildagliptin, intravenous administration of 
insulin five hours post-meal ingestion resulted in a marked 
suppression of glucagon to a nadir, which was not seen in 
the presence of placebo.28
It has also been proposed that DPP-4 inhibition alters 
insulin action and glucose effectiveness. Some31,32 but not 
all studies33 have shown increased glucose effectiveness 
when GLP-1 is administered in pharmacologic doses. 
Therefore, it is not an unreasonable expectation that similar 
effects may be seen with DPP-4 inhibition which increases 
endogenous levels of GLP-1. However, we observed no 
change in glucose effectiveness and insulin action after 
10 days of treatment with vildagliptin.28 In the same study, 
the glucose-lowering effects of exogenously-administered 
insulin (a model-independent measure of insulin action) 
was unchanged by vildagliptin. In contrast, a study where 
subjects were treated with vildagliptin for six weeks and a 
euglycemic hyperinsulinemic clamp was used to measure 
insulin-stimulated systemic glucose utilization, found the 
latter to be slightly but significantly higher with vildagliptin 
treatment.26 This however may be a reflection of decreased 
glucotoxicity and lipotoxicity associated with a longer 
duration of DPP-4 inhibitor therapy. In another short-term 
study, where a single dose of vildagliptin was administered, 
there was no improvement in glucose disposal,27 which is 
consistent with our findings.
Unlike GLP-1 and exenatide which delay gastric emptying 
when administered in pharmacologic doses, DPP-4 inhibition 
has little effect on gastrointestinal motility. Our study of 
people with type 2 diabetes treated with vildagliptin did not 
show a difference in gastric emptying,24 gastric volume or 
satiation.34 This is congruent with the observation that unlike 
the GLP-1 analogue exenatide, the DPP-4-inhibitors do not 
increase the frequency of gastrointestinal side-effects such 
as prandial fullness, nausea or vomiting.
The absence of effect of DPP-4 inhibition on gastric 
emptying raises the question whether all therapeutic actions 
of DPP-4 inhibitors are mediated by GLP-1. Indeed, there 
has been some controversy with regards to the mode of 
action of  DPP-4 inhibitors.35,36 Although all studies of  DPP-4 
inhibition demonstrate an increase in the level of circulating 
GLP-1, the magnitude of this change is arguably small.35 
The infusion of an equivalent amount of GLP-1 has little 
insulinotropic activity in healthy subjects and subjects 
with type 2 diabetes.37 However, GLP-1 concentration in 
the systemic circulation may be of a lesser physiologic 
relevance than the portal circulation concentrations and the 
local concentration in the lamina propria of gastrointestinal 
mucosa. Higher local and portal concentrations of GLP-1 
may activate afferent sensory nerves of the gut leading to 
increased vagal stimulatory activity to the pancreas.36 The 
potential role of this neural pathway is suggested by the 
finding of GLP-1 receptor expression in the nodose ganglion 
cells,38 as well as by an increase in vagal trunk activity seen 
after intraportal administration of GLP-1.39
The same parasympathetic nervous activation mechanism 
may explain the absence of effects of DPP-4 inhibitors on 
gastrointestinal motility. In a study during which GLP-1 
was infused intravenously in people with type 2 diabetes, 
glucose-lowering was observed with all doses, but gastric 
emptying was inhibited in a dose-dependent manner.40 This 
suggests that higher GLP-1 concentrations may be needed 
to produce effects on the afferent sensory neuron receptors 
of the gastrointestinal tract that result in slowing of intestinal 
motility.
Since DPP-4 inhibitors are weight-neutral and have no 
significant gastrointestinal effects it has been suggested 
that this may be explained by altered concentrations of 
peptides other than GLP-1, particularly NPY and PYY. 
NPY is an abundant neuropeptide in the central and 
peripheral nervous system, involved in the control of 
feeding and energy homeostasis. PYY is produced by 
endocrine cells of the small intestine and colon in response 
to a meal and has several inhibitory functions. Both are Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 86
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substrates of DPP-4 enzyme and their truncation by the 
enzyme reduces their activity on Y1 receptor located in 
the cerebral cortex while preserving agonist activity on 
Y2 and Y5 receptors.41
In contrast, studies in mice with combined genetic 
disruption of both GIP and GLP-1 receptors (double incretin 
receptor knockout) DIRKO mice provide evidence that GIP 
and GLP-1 are the principle peptides responsible for the 
glucose-lowering effects of DPP-4 inhibitors. When these mice 
were treated with vildagliptin for eight weeks, there was no 
improvement in insulin secretion and no lowering of blood 
glucose, whereas these effects were present in the wild-type 
control group.42 Other DPP-4 inhibitors were similarly 
ineffective in lowering blood glucose after an oral glucose 
challenge in DIRKO mice.43
In summary, it seems that DPP-4 inhibitors lower glucose 
concentrations through their effects on insulin and glucagon 
secretion. There is no consistent evidence that they improve 
insulin action or glucose effectiveness. Gastric emptying 
is not inhibited. These effects are most likely mediated 
by an increase in endogenous GLP-1, although additional 
mechanisms may be involved.
Pharmacology
The pharmacokinetics of vildagliptin have been studied in 
healthy subjects and people with type 2 diabetes.44,45 Oral 
doses of 25–100 mg administered once or twice daily were 
used. Vildagliptin is rapidly absorbed and is not subject 
to significant first-pass metabolism, resulting in 85% oral 
bioavailability.44 Administration of vildagliptin with food 
has no clinically relevant effect on bioavailability.46 Maximal 
concentration occurs one hour after administration regardless 
of the dose. Its elimination half-life in plasma is short 
(average 2.8 hrs), yet its effects on DPP-4 inhibition are long-
lasting with 86% and 95% 24-hour inhibitory effect at 25 mg 
twice daily and 100 mg twice daily doses, respectively.45 
This is likely related to the extensive distribution of the 
drug into the tissue: the volume of distribution in the steady 
state is 71 L.47
Vildagliptin undergoes hydrolysis in the liver, with a 
smaller (20%) contribution from the DPP-4 enzyme itself.44 
The principle hydrolysis reaction yields the major carboxylic 
metabolite which is inactive. This does not involve the p450 
system, making the potential for drug–drug interactions low. 
When vildagliptin was studied specifically in combination 
with commonly used antihypertensive medications 
(amlodipine, valsartan, and ramipril) no significant 
interactions were found.48 Final elimination of vildaglipitin 
metabolites is via the kidney, where one third of the drug is 
excreted in an unchanged form.44
Efficacy
A number of studies investigated the efficacy of vildagliptin in 
the treatment of drug-naïve patients with type 2 diabetes.49–54 
Mostly, these were six months in duration, with several 
studies spanning more than 12 months.49,50,52 Total doses of 
50 mg or 100 mg daily were used, administered on a once 
or twice daily schedule. Hemoglobin A1C (HbA1C) reduction 
from baseline ranged from 0.2 to 1.4%. The reduction was 
greatest in patients with a higher baseline HbA1C. Thus, in 
a 52-week trial of vildagliptin at a 50 mg daily dose where 
patients had a baseline HbA1C of 6.7, there was only a 0.2% 
reduction in HbA1C from baseline.49 However, in trials where 
baseline HbA1C was higher, greater effect of vildagliptin on 
HbA1C was observed. For example, in the trial comparing 
vildagliptin to metformin as initial monotherapy for type 2 
diabetes, there was a 1.0% reduction from a baseline HbA1C 
of  8.7% achieved on vildagliptin 100 mg daily.52 Similarly, a 
trial comparing acarbose to vildagliptin 50 mg twice daily as 
initial therapy in drug-naïve patients with a baseline HbA1C 
of 8.6%, a reduction of 1.4% was seen.55
In determining the potential therapeutic niche of vildagliptin, 
a number of questions arise. Will vildagliptin become a first-
line agent in the treatment of type 2 diabetes? Metformin, the 
current first-line therapy, has a long, well-established track 
record of efficacy and safety. A 52-week trial comparing met-
formin (1000 mg twice daily) with vildagliptin (50 mg twice 
daily) in drug-naïve patients with type 2 diabetes, showed 
that the reduction in HbA1C was significantly greater in the 
metformin group (1.4% reduction) compared to vildagliptin 
(1.0% reduction).52 Thus, noninferiority of vildagliptin to 
metformin was not established. The superiority of the metfor-
min in reducing HbA1C was primarily driven by the subgroup 
of patients with HbA1C  8.0%. In contrast, in patients with 
HbA1C  8.0, changes from baseline HbA1C were similar in 
metformin and vildagliptin treatment groups. Metformin also 
led to an average weight loss of approximately 2 kg, whereas 
vildagliptin was weight-neutral. Gastrointestinal side effects 
were twice as prevalent with metformin as with vildagliptin, 
leading to a higher discontinuation rate. Thus, for patients 
unable to tolerate metformin as first-line therapy due to gastro-
intestinal adverse effects, vildagliptin may provide a treatment 
alternative, and for patients with baseline HbA1C  8.0% there 
may not be an efficacy trade-off in this substitution.
Does vildagliptin have disease-modifying properties to 
justify its use in preventing the progression of type 2 diabetes? Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 87
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A 56-week extension of a previously mentioned 52-week trial 
of vildaglipitin in drug-naïve subjects with type 2 diabetes49 
proposed that vildagliptin attenuates the progressive deterio-
ration in β-cell function.50 However, the results were modest 
at best. Although HbA1C did not change significantly from 
baseline (6.6% in the vildagliptin-treated subjects) over the 
two-year treatment period; this was primarily driven by the 
treatment effect in the first year. In the second year, HbA1C 
increased significantly, albeit this increase was less than in 
the placebo group (0.2% increase for vildagliptin and 0.5% 
for placebo). A four-week washout period at the end of the 
study suggested that the effects on β-cell function and HbA1C 
may be maintained. However, the short duration of follow-up 
after the discontinuation of vildagliptin and lack of statistical 
robustness (p = 0.058 for between-group differences in the 
measure of β-cell function after washout) diminish the 
clinical significance of these findings.
Can vildagliptin be safely and effectively added as 
a second treatment agent and what advantages does it offer 
relative to other therapeutic options? A common scenario is 
failure to achieve target HbA1C on metformin monotherapy. 
In these patients, a sulfonylurea or thiazolidinedione is 
commonly added to improve glycemic control. In a 52-week 
trial where patients inadequately controlled on a maximum 
dose of metformin were randomized to receive glimepiride 
(mean dose 4.5 mg daily) or vildagliptin (50 mg twice 
daily), noninferiority of vildagliptin to glimepiride was 
demonstrated.56 Comparable HbA1C reduction was seen in 
both groups (-0.9% in patients with baseline HbA1C  8%) 
and a similar proportion of patients (54%–55%) in each 
group achieved HbA1C  7%. Notably, in the vildagliptin 
treatment group, a greater proportion of patients achieved 
target HbA1C without hypoglycemia (50.9% vs 44.3% in 
the glimepiride group). In marked contrast to glimepiride 
group, there were no severe hypoglycemic episodes among 
vildagliptin-treated patients and no discontinuation of therapy 
due to hypoglycemia. Another advantage of vildagliptin 
over glimepiride was that the former did not result in a 
weight gain, whereas glimepiride-treated subjects gained 
on average 1.5 kg.
Other possible clinical scenarios include inadequate 
glycemic control on monotherapy with either a sulfonylurea 
or a thiazolidinedione. Studies suggest that the addition 
of vildagliptin to glimepiride or pioglitazone results 
in a significant proportion of patients achieving target 
HbA1C  7%.57,58 When added to glimepiride 4 mg daily, 
a 50 mg dose of vildagliptin daily was similar to 100 mg 
daily in efficacy of glycemic control, with 21% of patients 
attaining goal HbA1C.57 50 mg dose was associated with no 
weight gain and less hypoglycemia than the 100 mg dose. 
When added to pioglitazone 45 mg daily, 100 mg dose of 
vildagliptin confers an efficacy advantage with 36% of 
patients reaching HbA1C goal compared to 29% of patients 
treated with the 50 mg dose.58 However, this is at the expense 
of an average 1.3 kg weight gain, which was not observed 
at the 50 mg dose. Interestingly, peripheral edema occurred 
more frequently in patients receiving vildagliptin added to 
pioglitazone than those receiving placebo with pioglitazone, 
but the frequency was unrelated to vildagliptin dose.
Addition of vildagliptin to an insulin program was 
examined in a 24-week trial that enrolled patients with a 
mean HbA1C of 8.4, despite taking an average of 82 units of 
insulin daily.59 Vildagliptin 50 mg twice daily added to the 
insulin program produced a reduction of mean HbA1C by 
0.3% relative to the placebo group. The overall effect was 
largely driven by patients older than 65 years who on average 
were taking less insulin (66 units daily). Insulin titration was 
permitted, leading to an increase in the insulin dose in both 
vildagliptin-treated and placebo-treated patients. Between the 
two groups, the difference in the insulin dose increase was 
not statistically significant. Nevertheless, vildagliptin-treated 
subjects experienced approximately 40% fewer hypoglycemic 
episodes and no severe hypoglycemia, leading the authors to 
speculate that DPP-4 inhibition may restore α-cell pancreatic 
function thereby improving counter-regulatory glucagon 
secretion. One theoretically-appealing regimen is to add 
vildagliptin to a 24-hour insulin such as glargine. However, 
at present, clinical trials are needed to examine the efficacy 
of this particular combination regimen.
Patients who may benefit from DPP-4 inhibitors in general 
and vildagliptin in particular are the elderly. Diabetes manage-
ment in this group is complicated by the frequent presence 
of renal impairment and other comorbidities. Efficacy and 
safety data pooled from five trials of vildagliptin that included 
subjects older than 65 years, suggests that vildagliptin is 
effective at lowering HbA1C in this population and may in 
fact lead to a greater decrease in fasting plasma glucose and 
a small, but statistically significant weight loss.60 There was 
no increase in drug-related adverse effects among the elderly 
when compared to younger patients, even though two-thirds 
of the older patients had a mildly impaired renal function. 
Overall rates of hypoglycemia were low (0.4%) and all the 
episodes were mild in severity. Thus, vildagliptin represents 
a promising option in the diabetes management of the older 
patients, but more dedicated long-term studies of this particu-
lar population are needed.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 88
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Safety and tolerability
In the efficacy trials previously described, vildagliptin was 
generally well tolerated. Incidence of hypoglycemia was 
low and the hypoglycemic episodes that occurred were mild. 
Notably, when used in combination with insulin, vildagliptin 
resulted in a significant reduction in the frequency of 
hypoglycemic events compared to the combination of 
insulin and placebo.59 Effects on bodyweight were neutral 
and not statistically different from placebo. Gastrointestinal 
effects such as diarrhea, nausea, and abdominal pain were 
at least two-fold less frequent with vildagliptin than with 
metformin.52
A meta-analysis that combined available data for 
vildagliptin and sitagliptin found an increased risk of 
nasopharyngitis (risk ratio 1.0–1.4), urinary tract infection 
(risk ratio 1.0–2.2), and headache (risk ratio 1.1–1.7).61 
An increased risk of headache was more evident with 
vildagliptin. Notably, gastrointestinal side effects were not 
increased relative to placebo.
The small increase in the risk of infection, although 
not statistically significant across all studies, may reflect 
the role of the DPP-4 enzyme in the regulation of immune 
function. Animal models suggest DPP-4 is important in 
the maintenance of the appropriate ratio of CD4+ T cells 
to natural killer cells in the spleen and in the circulation.62 
Several chemokines that attract monocytes, lymphocytes, 
and natural killer cells are potential substrates for DPP-4.63 
Cleavage by DPP-4 could activate chemokines and alter 
immune signaling, and DPP-4 inhibition may theoretically 
impair chemotaxis and result in an increased susceptibility 
to infection.
Conclusions
DPP-4 inhibitors are members of a relatively new class of 
pharmacotherapy for type 2 diabetes. They improve glycemic 
control by enhancing β-cell responsiveness to ambient 
glucose and lowering post-prandial levels of glucagon. These 
effects are primarily mediated by decreased GLP-1 clearance 
resulting in higher concentrations of GLP-1, especially 
in the portal circulation. Other potential mechanisms of 
action are currently the subject of investigation. DPP-4 
inhibitors effectively reduce HbA1C with a low incidence 
of hypoglycemia. Other features include weight neutrality, 
infrequent gastrointestinal side effects and safety even 
when renal impairment is present. These attributes could 
make these agents particularly useful in the treatment of 
elderly patients. Long-term outcome studies with a focus 
on micro- and macrovascular complications are needed to 
further define the role of DPP-4 inhibitors in the treatment 
of type 2 diabetes.
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